Collegium Pharmaceutical Stock News

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at William Blair reduced their Q1 2020 earnings per share estimates for shares of Collegium Pharmaceutical in a note issued to invest

STOUGHTON, Mass., April 23, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on SCYNEXIS (SCYX), with a price target of $3.50. The company's

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on SCYNEXIS ( SCYX – Research Report ), with a price target of $3.50 . The company’s shares closed last Tuesday

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA) today and set a price target of $33.00. The company's shares

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a

A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.

Analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will post $77.45 million in sales for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Collegium Phar

Collegium Pharmaceutical Inc (NASDAQ:COLL) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a d

Ballast Advisors LLC purchased a new position in Collegium Pharmaceutical Inc (NASDAQ:COLL) during the first quarter, according to the company in its most recent disclosure with the Securities and Exc

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Actinium Pharmaceuticals

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesda

Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) today. The company's shares closed last Wednesday at $16.19.

Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals ( AMPH – Research Report ) today. The company’s shares closed last Wednesday at $16.19. According to TipRanks.c